Flt3 Ligand Bioactivity and Pharmacology in Neoplasia

Publisher： Bentham Science Publishers

E-ISSN： 1875-5917|4|2|149-156

ISSN： 1568-0088

Source： Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol.4, Iss.2, 2004-06, pp. : 149-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FLt3 ligand increases dendritic cell count in prostate cancer

By  

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Cancer, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

Blackwell Publishing

Access to resources Recommend Favorite

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

By Tickenbrock Lara   Müller-Tidow Carsten   Berdel Wolfgang E   Serve Hubert  

Expert Opinion on Emerging Drugs, Vol. 11, Iss. 1, 2006-03 ,pp. : 153-165

Informa Healthcare

Access to resources Recommend Favorite

FLT3 as a Therapeutic Target in Childhood Acute Leukemia

By  

Current Drug Targets, Vol. 8, Iss. 6, 2007-06 ,pp. : 703-714

Bentham Science Publishers

Access to resources Recommend Favorite

FLT3 inhibitors for the treatment of autoimmune disease

By Whartenby Katharine A   Small Donald   Calabresi Peter A  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1685-1692

Informa Healthcare

Access to resources Recommend Favorite